logo
Quick Facts
  

Charles River To Collaborate With Axovia Therapeutics - Quick Facts

By RTTNews Staff Writer   ✉   | Published: | Follow Us On Google News

Charles River Laboratories International, Inc. (CRL) announced a plasmid DNA contract
development and manufacturing organization collaboration with Axovia Therapeutics. Charles River will manufacture High Quality gene of interest plasmid to support the development of Axovia's gene therapies for ciliopathies, including Bardet-Biedl Syndrome. Axovia will leverage Charles River's plasmid platform, eXpDNA, and premier expertise in plasmid DNA production, including HQ plasmid.

Axovia Therapeutics, an ALSA Ventures portfolio company, is developing the first gene therapies for ciliopathies and has a pipeline of products.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tamer-Than-Expected Inflation Data Leads To New Record Highs On Wall Street
With traders reacting positively to closely watched consumer price inflation data, stocks moved sharply higher during trading on Wednesday. The major averages added to Tuesday's gains, setting new record closing highs. The rally on Wall Street came following the release of a Labor Department report showing consumer prices in the U.S. rose by slightly less than expected in the month of April.
U.S. Business Inventories Edge Down In Line With Estimates In March
The Commerce Department released a report on Wednesday showing a modest decrease in business inventories in the U.S. in the month of March. The report said business inventories edged by 0.1 percent in March after climbing by 0.3 percent in February. The dip matched economist estimates.
U.S. Homebuilder Confidence Unexpectedly Slumps In May
With higher mortgage rates weighing on sentiment, the National Association of Home Builders released a report on Wednesday showing an unexpected deterioration in U.S. homebuilder confidence in the month of May. The report said the NAHB/Wells Fargo Housing Market Index tumbled to 45 in May from 51 in April. Economists had expected the index to come in unchanged.
Biotechnology Weekly Update - May 14, 2024

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Latest Updates on COVID-19
Read More
COVID-19: Drugs in Development
Follow RTT
Copyright © 2024 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap